<DOC>
	<DOCNO>NCT01679743</DOCNO>
	<brief_summary>Background : - Brain metastasis cancer cell spread brain primary cancer organ . These tumor remove surgically . However , researcher try find good way treat brain metastasis . A new drug , GRN1005 , design cross brain deliver cancer treatment drug paclitaxel treat tumor . Researchers want see well GRN1005 work brain metastasis breast lung cancer . Objectives : - To test safety effectiveness GRN1005 treat brain metastasis breast lung cancer . Eligibility : - Individuals least 18 year age breast lung cancer spread brain . Design : - Participants screen physical exam medical history . Blood urine sample collect . Tumor tissue sample may also collect . Imaging study also perform . - Participants breast cancer divide two group . Those whose cancer contain HER2 protein treat drug Herceptin well GRN1005 . Those without HER2 GRN1005 . - Participants lung cancer also GRN1005 . - All participant two dos GRN1005 , 3 week apart . On day second dose GRN1005 give , participant undergo surgery remove brain tumor . - Treatment monitor frequent blood test image study .</brief_summary>
	<brief_title>GRN1005 Brain Metastases From Breast Lung Cancer</brief_title>
	<detailed_description>Background : Brain metastasis common intra-cranial tumor adult approximately 170,000 new case diagnose United States annually . The incidence brain metastasis increase . Usually brain metastasis breast cancer occur diagnosis systemic metastasis ; approximately 10 25 % patient lung cancer brain metastasis diagnosis another 40 50 % develop course disease . Multiple factor contribute increase : age population , improve imaging technique , improvement treatment tumor lead prolonged survival , thereby allow emergence brain metastasis , brain generally regard sanctuary site blood brain barrier ( BBB ) . Lung cancer breast cancer lead tumor type , account approximately 50 % 15 - 20 % patient brain metastasis . This study evaluate ability 18F-FLT determine amount change uptake brain metastasis breast lung cancer one dose therapy GRN1005 , correlate intra-cranial response . FLT-PET utilizes radiolabeled form thymidine , incorporate DNA proliferate cell . 18F-FLT uptake correlate well 18F-FDG proliferation , tumor progression , survival . Because CNS uptake FLT low contrast FDG , make potentially useful evaluate CNS metastasis . We would like see image modality superior detection brain metastasis , monitor response therapy . Objectives : -Determine whether one cycle therapy GRN1005 associate change FLTPET uptake . Eligibility : - Adult patient ( great equal 18 year ) - Histologically cytologically-documented breast cancer ( HER2 status must know ) NSCLC - Presence resectable brain metastasis base evaluation neurosurgery . - At least one radiologically-confirmed measurable metastatic brain lesion . Design : - Pilot non-randomized trial without trastuzumab - Ten patient resectable brain metastasis breast cancer ten patient resectable brain metastasis NSCLC study . - Baseline imaging ( brain tumor protocol MRI DSC-PWI MRI , FLT-PET ) 1-14 day prior first dose GRN1005 . - Patients receive 1 dose GRN1005 day 1 study . - Repeat FLT-PET imaging MRIs do 1 cycle therapy prior surgery , day 21 . - On day surgery , patient receive second dose GRN1005 3 6 hour prior brain surgery . - PK study do dose GRN1005 . - Optional extra-cranial tumor biopsy perform GRN1005 administration . - Following surgery radiation therapy offer patient clinically indicate per radiation oncologist recommendation .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>INCLUSION CRITERIA : Adult patient ( great equal 18 year ) Histologically cytologicallydocumented breast cancer ( HER2 status must know ) NSCLC Presence resectable brain metastasis without prior radiotherapy . Patients must great 28 day WBRT SRS Presence resectable brain metastasis , assess neurosurgical evaluation . A brain tumor consider resectable purpose study locate cerebrum cerebellum . Tumors locate deep brain structure , include medulla , pons , midbrain , thalamus , basal ganglion consider nonresectable . The tumor must solitary , , accompany another tumor side brain also consider resectable criterion . At least one radiologicallyconfirmed measurable metastatic brain lesion ( great equal 1.0 centimeter longest diameter ) GdMRI brain le 14 day prior first dose GRN1005 ( Cycle 1 , Day 1 ) . The spatial resolution Philips Gemini TOF PET/CT 4millimeters [ FWHM , ( full width half maximum ) ] . One cm great 2 time FWHM anticipate great 70 % actual activity lesion visualize ( i.e . recover ) . It expect lesion great equal 1 centimeter sufficient FLT uptake . If lesion baseline image visualize FLT PET/CT , post therapy FLT imaging perform . These patient replace . Patients must neurologically stable , define stable dos corticosteroid anticonvulsant ( enzymeinducing antiepileptic drug ( EIAEDs ) , include phenytoin , phenobarbitol , carbamazepine , fosphenytoin , primidone , oxcarbazepine ) great equal 5 day prior obtain baseline GdMRI brain great equal 5 day prior first dose GRN1005 Karnofsky Performance Score ( KPS ) great equal 80 % ( equivalent Eastern Cooperative Oncology Group [ ECOG ] Performance Status 0 1 ) Life expectancy great 3 month Completed cytotoxic chemotherapy great equal 21 day ( every 3week regimen ) great equal 14 day ( every 2week weekly regimen ) prior first dose GRN1005 ( Cycle 1 , Day 1 ) ; clinically significant toxicity ( exclude alopecia ) must resolve less equal CTCAE v4.0 Grade 1 . Completed treatment noncytotoxic systemic drug ( e.g. , target drug ) great equal 14 day small molecule great equal 28 day monoclonal antibody ( e.g. , bevacizumab , exception trastuzumab bisphosphonates ) prior first dose GRN1005 ( Cycle 1 , Day 1 ) . All clinically significant toxicity ( exclude alopecia ) must resolve less equal CTCAE v4.0 Grade 1 . Adequate laboratory test result organ system less equal 14 day prior first dose GRN1005 , follow : Absolute neutrophil count ( ANC ) great equal 1.5 time 10 ( 9 ) /L Hgb great equal 9.0 gram per deciliter Platelets great equal 100 time 10 ( 9 ) /L Total bilirubin le 1.6 milligram per deciliter le upper limit normal ( ULN ) . Serum bilirubin less 2 time ULN patient Gilbert syndrome Aspartate aminotransferase ( AST ; SGOT ) alanine aminotransferase ( ALT ; SGPT ) less 2.5 time ULN . AST , ALT le 5 time ULN patient document liver metastasis Alkaline phosphatase less 2.5 time ULN . For patient document liver bone metastasis , alkaline phosphatase less 5 time ULN Serum creatinine le 1.5 milligram per deciliter creatinine clearance great equal 45 millliter per minute Negative pregnancy test less equal 72 hour prior Cycle 1 , Day 1 GRN1005 ( woman reproductive potential ) Patients HER2positive disease trastuzumab willing able continue receive trastuzumab accordance standard institutional practice prescribe information ( EF great equal 50 % history trastuzumab relate CHF great equal 16 % absolute decrease LVEF pretreatment value LVEF value institutional limit normal great equal 10 % absolute decrease LVEF pretreatment value ) . If criterion meet , trastuzumab administer protocol . Ability subject Legally Authorized Representative ( LAR ) ( patient deem treat physician cognitively impaired questionably impaired way ability patient give inform consent questionable ) understand willingness sign write informed consent document indicate aware investigational nature study . EXCLUSION CRITERIA : NCI CTCAE v4.0 Grade great equal 2 neuropathy CNS disease require immediate neurosurgical intervention ( e.g. , resection , shunt placement , etc . ) Known leptomeningeal disease Known severe hypersensitivity allergy paclitaxel component Treatment P450 CYP 3A4 2C8 enzymeinducing anticonvulsant drug less equal 14 day prior first dose GRN1005 ( Cycle 1 , Day 1 ) Patients presence infection include abscess fistula , infection hepatitis B C HIV Any evidence severe uncontrolled systemic disease , clinically significant cardiovascular ( include arrhythmia ) , pulmonary , hepatic , renal , metabolic disease ; woundhealing disorder ; ulcer ; bone fracture History interstitial lung disease ( e.g. , pneumonitis pulmonary fibrosis ) evidence clinically significant interstitial lung disease chest CT scan Severe conduction disturbance include clinically significant QTc prolongation define QTc great 450 millisecond woman QTc great 440 millisecond men ( unless pacemaker place ) . Women men reproductive potential consenting use doublebarrier contraceptive method ( e.g. , diaphragm plus condom ) abstinence study , screen 3 month last GRN1005 administration , applicable , 6 month last trastuzumab administration Women pregnant breastfeeding Prior GRN1005 treatment Allergy gadolinium use MRI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 11, 2014</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Metastatic Lung Cancer</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>18FLT</keyword>
	<keyword>Surgery</keyword>
</DOC>